Table 1.

Baseline characteristics and cycle and dose data for all 131 patients treated on NCI 1312 or only for the NIH cohort

Data for all 131 patients on NCI 1312
Characteristic		Number of patients
Gender	Total	CTCL	PTCL
Male	82	57	25
Female	49	27	22
Diagnosis	131	84	47
Prior doxorubicin
Yes	66	22	44
No	65	62	3
ECOG
0	44	26	18
1	71	47	24
2	16	11	5
Cycles administered
1–2	36	14	22
3–5	43	34	9
≥6	52	36	16
	Median (range)
Age	59.4 (27.6–84.8)	59.2 (28.2–84.8)	59.6 (27.6–84.3)
Cycles	4 (1–82)	4.5 (1–79)	3 (1–82)
Doses	12.0 (1–244)	12.5 (2–158)	9 (1–244)
	Doses
Total doses	3359	2067	1292
Data for NIH cohort
Characteristic		Number of patients
Gender	Total	CTCL	PTCL
Male	40	29	11
Female	23	13	10
Diagnosis	63	42	21
Prior doxorubicin
Yes	33	12	21
No	30	30	0
ECOG
0	9	4	5
1	46	32	14
2	8	6	2
Cycles administered
1–2	19	8	11
3–5	19	16	3
≥6	25	18	7
	Median (range)
Age	53.3 (27.6–80.3)	55.5 (28.2–80.3)	57.6 (27.6–79.4)
Cycles	4 (1–79)	4 (1–79)	2 (1–29)
Doses	12 (1–158)	12 (2–158)	6 (1–81)
	Doses
Total doses	1403	1005	398